On the heels of news that the Alzheimer’s drug development pipeline is nearly dry, there’s a glimmer of hope.
Research presented today at the 2014 Alzheimer’s Association International conference in Copenhagen shows that a new Alzheimer’s drug may help slow early stages of the disease.
Researchers in this multi-center trial looked at over 400 patients with mild-to-moderate Alzheimer’s disease for 73 weeks in two phase-two studies, which are designed to test the effectiveness and safety of new drugs.
Some patients were given a high dose of the drug, Crenezumab, intravenously every four weeks.
Others were given a low dose injection of the drug under the skin every other week.
And the rest were given a placebo.
The goal of the research was to delay cognitive and functional decline in the patients.
The drug did not meet the goal completely, but in milder forms of the disease, the high-dose i-v form of the drug did show evidence of slowing the decline of cognitive abilities.
According to the Alzheimer’s Association, an estimated 5.5 million people in the United States have Alzheimer’s disease.